Application of molecular imaging technology in evaluating the inhibiting effect of apigenin in vivo on subcutaneous hepatocellular carcinoma

doi:10.1016/j.bbrc.2017.04.029

CORC > 自动化研究所 > 中国科学院自动化研究所 > 中国科学院分子影像重点实验室

	Application of molecular imaging technology in evaluating the inhibiting effect of apigenin in vivo on subcutaneous hepatocellular carcinoma
	Li, Gang 1; Chi, Chong-wei 2; Shao, Xian-Fang 1; Fang, Chi-Hua 3
刊名	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
	2017-05-20
卷号	487 期号:1 页码:122-127
关键词	Apigenin Molecular Imaging Hepatocellular Carcinoma
DOI	10.1016/j.bbrc.2017.04.029
文献子类	Article
英文摘要	The aim of this study was to evaluate the inhibiting effect of apigenin on liver cancer in vivo based on the optical molecular imaging method. Subcutaneous liver tumor models were established using respective 1 x 10(6) firefly luciferase (fLuc) and green fluorescent protein (GFP) labeled human hepatocellular carcinoma cells (HepG2-fLuc and HepG2-GFP cells) in 20 BALB/c nude mice which were randomly divided into two groups, 10 in each group. After the tumor cells were implanted 15 days, apigenin was administered through intraperitoneal injection in group B, the other ten mice as control group A. Bioluminescence imaging (BLI) and fluorescence molecular imaging (FMI) were carried out for the follow-up of subcutaneous tumor model. As time goes on, intensity and distribution of bioluminescence and fluorescence of tumours increased gradually with the growth of tumours little by little. The whole process of observation was in accordance with known activities of HCC in the human liver. The tumor volume and tumor weight were significant lower in group B than in group A (p < 0.05), Subcutaneous tumours in the apigenin treatment group B based on BLI and FMI were significantly inhibited compared to the control group A (p < 0.05). Apigenin could be expected as a new drug to treat hepatocellular carcinoma. Optical molecular imaging technology enabled the non-invasive and reliable assessment of anti-tumor drug efficacy on liver cancer. (C) 2017 Elsevier Inc. All rights reserved.
WOS关键词	TUMOR ; CANCER ; MICE ; TOMOGRAPHY ; MOUSE ; CELLS ; MODEL
WOS研究方向	Biochemistry & Molecular Biology ; Biophysics
语种	英语
WOS记录号	WOS:000400954300019
资助机构	National Basic Research Program of China (973 Program)(2011CB707700) ; National Natural Science Foundation of China(81027002 ; Chinese Academy of Sciences Visiting Professorship for Senior International Scientists(2012T1G0036) ; National High Technology Research and Development Program of China (863 Program)(2006AA02Z346 ; Chinese Medicine Foundation of Hunan Province, China(20171) ; Guangdong Province(2010A090100032) ; Chinese Academy of Sciences(2010A090100032) ; Science and Technology Project of Guangdong Province, China(200304303 ; Industrial Technology Research and Development Program of Guangdong Province(2012A030400013) ; 81170458) ; 2012AA021105) ; 2011t1031800088 ; 2011B031800091)
内容类型	期刊论文
源URL	[http://ir.ia.ac.cn/handle/173211/15098]
专题	自动化研究所_中国科学院分子影像重点实验室
作者单位	1.Hunan Univ Chinese Med, Changde Tradit Chinese Med Hosp 1, Changsha 410208, Hunan, Peoples R China 2.Chinese Acad Sci, Key Lab Mol Imaging, Beijing, Peoples R China 3.Southern Med Univ, Zhujiang Hosp, Dept Hepatobiliary Surg, Guangzhou, Guangdong, Peoples R China
推荐引用方式 GB/T 7714	Li, Gang,Chi, Chong-wei,Shao, Xian-Fang,et al. Application of molecular imaging technology in evaluating the inhibiting effect of apigenin in vivo on subcutaneous hepatocellular carcinoma[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,2017,487(1):122-127.
APA	Li, Gang,Chi, Chong-wei,Shao, Xian-Fang,&Fang, Chi-Hua.(2017).Application of molecular imaging technology in evaluating the inhibiting effect of apigenin in vivo on subcutaneous hepatocellular carcinoma.BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,487(1),122-127.
MLA	Li, Gang,et al."Application of molecular imaging technology in evaluating the inhibiting effect of apigenin in vivo on subcutaneous hepatocellular carcinoma".BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 487.1(2017):122-127.